Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgery Today
Published in: Surgery Today 8/2016

01-08-2016 | Original Article

Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan

Authors: Hideaki Kimura, Kenichi Takahashi, Kitaro Futami, Hiroki Ikeuchi, Kenji Tatsumi, Kazuhiro Watanabe, Kiyoshi Maeda, Yusuke Watadani, Riichiro Nezu, Hitoshi Kameyama, Sayumi Nakao, Kiyotaka Kurachi, Masayuki Hotokezaka, Koki Otsuka, Toshiaki Watanabe, Heita Ozawa

Published in: Surgery Today | Issue 8/2016

Login to get access

Abstract

Purpose

The aim of the study is to assess the relationship between the introduction of biologic and immunosuppressant therapy and the number of patients undergoing surgery for ulcerative colitis (UC).

Methods

A questionnaire survey about patients undergoing surgery for UC was sent to 26 teaching hospitals throughout Japan. The questionnaire period spanned from 2008 to 2013, to account for the introduction of tacrolimus (2009) and infliximab (2010).

Results

The total number of patients who underwent surgery was 297, 291, 273, 255, 300, and 305 in 2008, 2009, 2010, 2011 2012, and 2013, respectively. The emergency surgery rate remained stable at 32–34 % each year. The proportion of patients who underwent surgery for cancer increased from 13.8 % in 2008 to 20 % in 2013. In 2013, 41, 38, and 6 % of patients who underwent surgery had received treatment with a biologic, tacrolimus, and cyclosporine, respectively. No institution reported an increase in postoperative complications among patients treated with immunosuppressive drugs.

Conclusions

The number of patients undergoing surgery decreased temporarily soon after infliximab and tacrolimus first became widely available, but subsequently increased again. The emergency surgery rate remained unchanged throughout the study period. These data show that immunosuppressive drugs have had little effect on the risk of postoperative complications.
Literature
1.
2.
Hiwatashi N, Yao T, Watanabe H, Hosoda S, Kobayashi K, Saito T, et al. Long-term follow-up study of ulcerative colitis in Japan. J Gastroenterol. 1995;30(Suppl 8):13–6.PubMed
3.
Annual report of the research committee of intractable inflammatory bowel disease, 2006. The Ministry of Health and Welfare of Japan, Tokyo; 2007 (in Japanese).
4.
Annual report of the research committee of intractable inflammatory bowel disease, 2012. The Ministry of Health and Welfare of Japan, Tokyo; 2013 (in Japanese).
5.
Hata K, Kazama S, Nozawa H, Kawai K, Kiyomatsu T, Tanaka J, et al. Laparoscopic surgery for ulcerative colitis: a review of the literature. Surg Today. 2015;45:933–8.CrossRefPubMed
6.
Moore SE, McGrail KM, Peterson S, Raval MJ, Karimuddin AA, Phang PT, et al. Infliximab in ulcerative colitis: the Impact if preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia. Can Dis Colon Rectum. 2014;57:83–90.CrossRefPubMed
7.
Williet N, Pillot C, Oussalah A, Billioud V, Chevaux JB, Bresler L, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis. 2012;18:1641–6.CrossRefPubMed
8.
Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447–58.CrossRefPubMed
9.
Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41:21–8.CrossRefPubMed
10.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: Special situations. J Crohns Colitis. 2013; 7:1–33.
11.
Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis. 2013;28:287–93.CrossRefPubMed
12.
Yoshimura N, Fujiwara T, Kawaguchi T, Sako M, Takazoe K. The clinical efficacy of therapeutic strategies in patients with severe refractory ulcerative colitis (in Japanese). Syokakinaika. 2013;57:542–8.
13.
Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2010;31:486–92.CrossRefPubMed
14.
Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther. 2012;36:922–8.CrossRefPubMed
15.
Nelson R, Liao C, Fichera A, Rubin DT, Pekow J. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014;20:14–20.CrossRefPubMedPubMedCentral
16.
Uchino M, Ikeuchi H, Matsuoka H, Bando T, Ichiki K, Nakajima K, et al. Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis. Int J Colorectal Dis. 2013;28:1295–306.CrossRefPubMed
17.
Gu J, Remzi FH, Shen B, Vogel JD, Kiran RP. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-α therapy. Dis Colon Rectum. 2013;56:1243–52.CrossRefPubMed
18.
Yamamoto T. Letter: The effects of preoperative infliximab on complications after surgery for ulcerative colitis. Aliment Pharmacol Ther. 2012;36:1106–7 (author reply 1107–8).CrossRefPubMed
19.
Ikeuchi H, Uchino M, Matsuoka H, Bando T, Hirata A, Takesue Y, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44:39–43.CrossRefPubMed
20.
Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97:404–9.CrossRefPubMed
21.
Powar MP, Martin P, Croft AR, Walsh A, Petersen D, Stevenson AR, et al. Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy. Colorectal Dis. 2013;15:374–9.CrossRefPubMed
Metadata
Title
Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan
Authors
Hideaki Kimura
Kenichi Takahashi
Kitaro Futami
Hiroki Ikeuchi
Kenji Tatsumi
Kazuhiro Watanabe
Kiyoshi Maeda
Yusuke Watadani
Riichiro Nezu
Hitoshi Kameyama
Sayumi Nakao
Kiyotaka Kurachi
Masayuki Hotokezaka
Koki Otsuka
Toshiaki Watanabe
Heita Ozawa
Publication date
01-08-2016
Publisher
Springer Japan
Published in
Surgery Today / Issue 8/2016
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-015-1259-3

Other articles of this Issue 8/2016

Surgery Today 8/2016 Go to the issue

Original Article

The oncological outcomes of segmentectomy in clinical-T1b lung adenocarcinoma with a solid-dominant appearance on thin-section computed tomography

Original Article

Recovery of gastric ileus following laparoscopic ventral rectopexy within an enhanced recovery protocol

Original Article

Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn’s disease

Original Article

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin

Original Article

The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis

Original Article

Management of unexpected intraoperative bleeding during thoracoscopic pulmonary resection: a single institutional experience